Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
News|Articles|September 2, 2003
- Pharmaceutical Technology-09-02-2003
- Volume 27
- Issue 9
CROs Hoping for Research Burst in Second Half of 2003
Author(s)Jim Miller
CROs and contract manufacturers had a decent second quarter, but they are hoping that Big Pharma comes through with a burst of trial start-ups in the second half of 2003.
Advertisement
Articles in this issue
about 23 years ago
September 2003about 23 years ago
In the Spotlight September 2003about 23 years ago
Counterfeiting, Compliance, and Controlsabout 23 years ago
September 2003about 23 years ago
Disposable Filtration Lightens Cleaning and Validation LoadAdvertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Advertisement
Advertisement